{"id":5932,"date":"2020-07-30T14:12:49","date_gmt":"2020-07-30T12:12:49","guid":{"rendered":"http:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/07\/ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL.pdf"},"modified":"2020-07-30T14:14:06","modified_gmt":"2020-07-30T12:14:06","slug":"ent-eo2401-fih-ph1-2-in-gbm-final-2","status":"inherit","type":"attachment","link":"https:\/\/www.seventure.fr\/en\/enterome-initiates-first-clinical-trial-with-eo2401-an-innovative-microbiomeantigen-based-cancer-immunotherapy-candidate-targeting-aggressive-brain-cancer\/ent-eo2401-fih-ph1-2-in-gbm-final-2\/","title":{"rendered":"ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL"},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false},"class_list":["post-5932","attachment","type-attachment","status-inherit","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL | Seventure<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/07\/ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL.pdf\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/07\/ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL.pdf\",\"url\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/07\/ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL.pdf\",\"name\":\"ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL | Seventure\",\"isPartOf\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\"},\"datePublished\":\"2020-07-30T12:12:49+00:00\",\"dateModified\":\"2020-07-30T12:14:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/07\/ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL.pdf#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/07\/ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL.pdf\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/07\/ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL.pdf#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.seventure.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enterome initiates first clinical trial with EO2401 \u2013 an innovative microbiomeantigen based cancer immunotherapy candidate targeting aggressive brain cancer\",\"item\":\"https:\/\/www.seventure.fr\/en\/enterome-initiates-first-clinical-trial-with-eo2401-an-innovative-microbiomeantigen-based-cancer-immunotherapy-candidate-targeting-aggressive-brain-cancer\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\",\"url\":\"https:\/\/www.seventure.fr\/en\/\",\"name\":\"Seventure\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.seventure.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL | Seventure","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/07\/ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL.pdf","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/07\/ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL.pdf","url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/07\/ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL.pdf","name":"ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL | Seventure","isPartOf":{"@id":"https:\/\/www.seventure.fr\/en\/#website"},"datePublished":"2020-07-30T12:12:49+00:00","dateModified":"2020-07-30T12:14:06+00:00","breadcrumb":{"@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/07\/ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL.pdf#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/07\/ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL.pdf"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/07\/ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL.pdf#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.seventure.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Enterome initiates first clinical trial with EO2401 \u2013 an innovative microbiomeantigen based cancer immunotherapy candidate targeting aggressive brain cancer","item":"https:\/\/www.seventure.fr\/en\/enterome-initiates-first-clinical-trial-with-eo2401-an-innovative-microbiomeantigen-based-cancer-immunotherapy-candidate-targeting-aggressive-brain-cancer\/"},{"@type":"ListItem","position":3,"name":"ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL"}]},{"@type":"WebSite","@id":"https:\/\/www.seventure.fr\/en\/#website","url":"https:\/\/www.seventure.fr\/en\/","name":"Seventure","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.seventure.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"description":{"rendered":"<p class=\"attachment\"><a href='https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/07\/ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL.pdf'><img loading=\"lazy\" decoding=\"async\" width=\"212\" height=\"300\" src=\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/07\/ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL-pdf-212x300.jpg\" class=\"attachment-medium size-medium\" alt=\"\" \/><\/a><\/p>\n"},"caption":{"rendered":""},"alt_text":"","media_type":"file","mime_type":"application\/pdf","media_details":{"sizes":{"thumbnail":{"file":"ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL-pdf-106x150.jpg","width":106,"height":150,"mime_type":"image\/jpeg","source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/07\/ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL-pdf-106x150.jpg"},"medium":{"file":"ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL-pdf-212x300.jpg","width":212,"height":300,"mime_type":"image\/jpeg","source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/07\/ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL-pdf-212x300.jpg"},"large":{"file":"ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL-pdf-724x1024.jpg","width":724,"height":1024,"mime_type":"image\/jpeg","source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/07\/ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL-pdf-724x1024.jpg"},"full":{"file":"ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL-pdf.jpg","width":1058,"height":1497,"mime_type":"application\/pdf","source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/07\/ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL-pdf.jpg"}}},"post":5934,"source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2020\/07\/ENT-EO2401-FIH-Ph1-2-in-GBM-FINAL.pdf","_links":{"self":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media\/5932","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media"}],"about":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/types\/attachment"}],"author":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/comments?post=5932"}]}}